Ekso Bionics EKSO has reported a significant drop in its second-quarter revenue, recording $2.06 million compared to $4.95 million in the same period last year. The decline was primarily attributed to temporary delays in finalizing several multi-device Enterprise Health sales.
According to the company's CEO, Scott Davis, efforts are underway to recover in the latter half of the year. The company is focusing on overcoming these sales deferrals and meeting the projected demand for their Enterprise Health solutions. Moreover, Ekso Bionics anticipates further growth driven by their Personal Health segment, which has already seen a more than 50% increase year-over-year in the first half of 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Ekso Bionics Holdings Inc EKSO is $37.50 with a high estimate of $60.00 and a low estimate of $15.00. The average target implies an upside of 727.81% from the current price of $4.53. More detailed estimate data can be found on the Ekso Bionics Holdings Inc (EKSO) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Ekso Bionics Holdings Inc's EKSO average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Ekso Bionics Holdings Inc EKSO in one year is $14.38, suggesting a upside of 217.44% from the current price of $4.53. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Ekso Bionics Holdings Inc (EKSO) Summary page.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
